USD
+$0.00
(+0.00%
)At Close (As of Sep 5, 2025)
$4.99B
Market Cap
-
P/E Ratio
-5.4
EPS
$71.13
52 Week High
$30.04
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | -$75M |
Total Revenue | $35M |
Cost Of Revenue | $110M |
Costof Goods And Services Sold | $110M |
Operating Income | -$467M |
Selling General And Administrative | $73M |
Research And Development | $321M |
Operating Expenses | $504M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | - |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $19M |
Income Before Tax | -$363M |
Income Tax Expense | $3.6M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$366M |
Comprehensive Income Net Of Tax | - |
Ebit | -$467M |
Ebitda | -$447M |
Net Income | -$366M |
Field | Value (USD) |
---|---|
Total Assets | $2.2B |
Total Current Assets | $1.9B |
Cash And Cash Equivalents At Carrying Value | $298M |
Cash And Short Term Investments | $298M |
Inventory | - |
Current Net Receivables | $25M |
Total Non Current Assets | $305M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | - |
Investments | - |
Long Term Investments | $0 |
Short Term Investments | $1.6B |
Other Current Assets | $8.3M |
Other Non Current Assets | - |
Total Liabilities | $310M |
Total Current Liabilities | $88M |
Current Accounts Payable | $15M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $17M |
Total Non Current Liabilities | $222M |
Capital Lease Obligations | $224M |
Long Term Debt | - |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $224M |
Other Current Liabilities | $52M |
Other Non Current Liabilities | $3.4M |
Total Shareholder Equity | $1.9B |
Treasury Stock | - |
Retained Earnings | -$1.4B |
Common Stock | $2.7M |
Common Stock Shares Outstanding | $84M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$143M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $19M |
Capital Expenditures | $1.9M |
Change In Receivables | - |
Change In Inventory | - |
Profit Loss | - |
Cashflow From Investment | -$280M |
Cashflow From Financing | $332M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | - |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$366M |
Field | Value (USD) |
---|---|
Gross Profit | -$75M |
Total Revenue | $35M |
Cost Of Revenue | $110M |
Costof Goods And Services Sold | $110M |
Operating Income | -$467M |
Selling General And Administrative | $73M |
Research And Development | $321M |
Operating Expenses | $504M |
Investment Income Net | - |
Net Interest Income | - |
Interest Income | - |
Interest Expense | - |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $19M |
Income Before Tax | -$363M |
Income Tax Expense | $3.6M |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$366M |
Comprehensive Income Net Of Tax | - |
Ebit | -$467M |
Ebitda | -$447M |
Net Income | -$366M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
CRISPR Therapeutics AG, a gene editing company, focuses on the development of gene-based transformative drugs for serious human diseases. The company is headquartered in Zug, Switzerland.